trial

Transcranial Alternating Current Stimulation (tACS) for Cognitive Impairments in Patients With Schizophrenia

NCTId NCT03756610
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Unknown
Enrollment 90 (estimated)
Sponsored by Shanghai Mental Health Center
Primary completion 2019-12
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Unknown
Enrollment
90 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2018-11
Primary completion
2019-12
Eligibility
ALL · 18 Years · 60 Years

Interventions & indications

Drugs
Active tACSActive boosting

Sponsors

Shanghai Mental Health CenterLead Sponsor

Investigators

1
Chunbo Li, Ph.D.Principal Investigator

Sites

1 total
Shanghai, China

Facts & assertions

4 sourced
Enrollment
90
Phase
NA
Primary Completion Date
2019-12
Status
UNKNOWN
relationships
The graph out of here
drug
Active tACS
drug
Active boosting
drug
lead_sponsor
Shanghai Mental Health Center
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Chunbo Li, Ph.D.
person